<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:38:58Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9928626" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9928626</identifier>
        <datestamp>2023-02-16</datestamp>
        <setSpec>jco</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Clin Oncol</journal-id>
              <journal-id journal-id-type="hwp">jco</journal-id>
              <journal-id journal-id-type="publisher-id">JCO</journal-id>
              <journal-title-group>
                <journal-title>Journal of Clinical Oncology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0732-183X</issn>
              <issn pub-type="epub">1527-7755</issn>
              <publisher>
                <publisher-name>Wolters Kluwer Health</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9928626</article-id>
              <article-id pub-id-type="pmcid">PMC9928626</article-id>
              <article-id pub-id-type="pmc-uid">9928626</article-id>
              <article-id pub-id-type="pmid">36288547</article-id>
              <article-id pub-id-type="pmid">36288547</article-id>
              <article-id pub-id-type="publisher-id">JCO.22.00739</article-id>
              <article-id pub-id-type="doi">10.1200/JCO.22.00739</article-id>
              <article-id pub-id-type="art-access-id">00019</article-id>
              <article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>ORIGINAL REPORTS</subject>
                  <subj-group>
                    <subject>Thoracic Oncology</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3430-3213</contrib-id>
                  <name>
                    <surname>Camidge</surname>
                    <given-names>D. Ross</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref rid="aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="cor1" ref-type="corresp"/>
                  <xref rid="con1" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Barlesi</surname>
                    <given-names>Fabrice</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="con12" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4925-8243</contrib-id>
                  <name>
                    <surname>Goldman</surname>
                    <given-names>Jonathan W.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="con4" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4349-2028</contrib-id>
                  <name>
                    <surname>Morgensztern</surname>
                    <given-names>Daniel</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="con14" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7397-2009</contrib-id>
                  <name>
                    <surname>Heist</surname>
                    <given-names>Rebecca</given-names>
                  </name>
                  <degrees>MD, MPH</degrees>
                  <xref rid="aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                  <xref rid="con8" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8645-8068</contrib-id>
                  <name>
                    <surname>Vokes</surname>
                    <given-names>Everett</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff7" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                  <xref rid="con16" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1303-0447</contrib-id>
                  <name>
                    <surname>Spira</surname>
                    <given-names>Alex</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref rid="aff8" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                  <xref rid="con10" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6249-7209</contrib-id>
                  <name>
                    <surname>Angevin</surname>
                    <given-names>Eric</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref rid="aff9" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                  <xref rid="con6" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Su</surname>
                    <given-names>Wu-Chou</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff10" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                  <xref rid="con2" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8721-1609</contrib-id>
                  <name>
                    <surname>Hong</surname>
                    <given-names>David S.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff11" ref-type="aff">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7579-1175</contrib-id>
                  <name>
                    <surname>Strickler</surname>
                    <given-names>John H.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff12" ref-type="aff">
                    <sup>12</sup>
                  </xref>
                  <xref rid="con5" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Motwani</surname>
                    <given-names>Monica</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff13" ref-type="aff">
                    <sup>13</sup>
                  </xref>
                  <xref rid="con15" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dunbar</surname>
                    <given-names>Martin</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff13" ref-type="aff">
                    <sup>13</sup>
                  </xref>
                  <xref rid="con9" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3711-8718</contrib-id>
                  <name>
                    <surname>Parikh</surname>
                    <given-names>Apurvasena</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff14" ref-type="aff">
                    <sup>14</sup>
                  </xref>
                  <xref rid="con17" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Noon</surname>
                    <given-names>Elysa</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff13" ref-type="aff">
                    <sup>13</sup>
                  </xref>
                  <xref rid="con11" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Blot</surname>
                    <given-names>Vincent</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff13" ref-type="aff">
                    <sup>13</sup>
                  </xref>
                  <xref rid="con7" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wu</surname>
                    <given-names>Jun</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff13" ref-type="aff">
                    <sup>13</sup>
                  </xref>
                  <xref rid="con3" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2235-6636</contrib-id>
                  <name>
                    <surname>Kelly</surname>
                    <given-names>Karen</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff15" ref-type="aff">
                    <sup>15</sup>
                  </xref>
                  <xref rid="con13" ref-type="fn"/>
                </contrib>
                <aff id="aff1"><label><sup>1</sup></label>University of Colorado Cancer Center, Aurora, CO</aff>
                <aff id="aff2"><label><sup>2</sup></label>Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Inserm U911 CRO2, Marseille, France</aff>
                <aff id="aff3"><label><sup>3</sup></label>Medical Oncology Department, Gustave Roussy, Villejuif, France</aff>
                <aff id="aff4"><label><sup>4</sup></label>David Geffen School of Medicine at UCLA, Los Angeles, CA</aff>
                <aff id="aff5"><label><sup>5</sup></label>Washington University School of Medicine, St Louis, MO</aff>
                <aff id="aff6"><label><sup>6</sup></label>Massachusetts General Hospital Cancer Center, Boston, MA</aff>
                <aff id="aff7"><label><sup>7</sup></label>University of Chicago Medicine, Chicago, IL</aff>
                <aff id="aff8"><label><sup>8</sup></label>Virginia Cancer Specialists Research Institute, Fairfax, VA</aff>
                <aff id="aff9"><label><sup>9</sup></label>Drug Development Department (DITEP), Gustave Roussy, Villejuif, France</aff>
                <aff id="aff10"><label><sup>10</sup></label>National Cheng Kung University Hospital, Tainan, Taiwan</aff>
                <aff id="aff11"><label><sup>11</sup></label>The University of Texas MD Anderson Cancer Center, Houston, TX</aff>
                <aff id="aff12"><label><sup>12</sup></label>Duke University Medical Center, Durham, NC</aff>
                <aff id="aff13"><label><sup>13</sup></label>AbbVie Inc, North Chicago, IL</aff>
                <aff id="aff14"><label><sup>14</sup></label>AbbVie Inc, Redwood City, CA</aff>
                <aff id="aff15"><label><sup>15</sup></label>University of California Davis Comprehensive Cancer Center, Sacramento, CA</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1">D. Ross Camidge, MD, PhD, University of Colorado Cancer Center, 1665 Aurora Ct, Aurora, CO 80045; e-mail: <email>Ross.Camidge@ucuanschutz.edu</email>.</corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <day>10</day>
                <month>2</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>26</day>
                <month>10</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>26</day>
                <month>10</month>
                <year>2022</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>41</volume>
              <issue>5</issue>
              <fpage>1105</fpage>
              <lpage>1115</lpage>
              <history>
                <date date-type="received">
                  <day>29</day>
                  <month>3</month>
                  <year>2022</year>
                </date>
                <date date-type="rev-recd">
                  <day>19</day>
                  <month>7</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>7</day>
                  <month>9</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2022 by American Society of Clinical Oncology</copyright-statement>
                <copyright-year>2022</copyright-year>
                <copyright-holder>American Society of Clinical Oncology</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p>
                </license>
              </permissions>
              <self-uri xlink:href="jco-41-1105.pdf"/>
              <related-object source-id-type="registry-name" document-id="NCT02099058" document-id-type="clinical-trial-number" source-type="clinical-trials-registry" source-id="ClinicalTrials.gov" id="d64e346"/>
              <abstract>
                <title>PURPOSE</title>
                <p>Overexpression of c-Met protein and epidermal growth factor receptor (<italic toggle="yes">EGFR</italic>) mutations can co-occur in non–small-cell lung cancer (NSCLC), providing strong rationale for dual targeting. Telisotuzumab vedotin (Teliso-V), a first-in-class antibody-drug conjugate targeting c-Met, has shown a tolerable safety profile and antitumor activity as monotherapy. Herein, we report the results of a phase Ib study (ClinicalTrials.gov identifier: <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT02099058" ext-link-type="uri">NCT02099058</ext-link>) evaluating Teliso-V plus erlotinib, an EGFR tyrosine kinase inhibitor (TKI), in patients with c-Met–positive (+) NSCLC.</p>
                <sec>
                  <title>PATIENTS AND METHODS</title>
                  <p>This study evaluated Teliso-V (2.7 mg/kg once every 21 days) plus erlotinib (150 mg once daily) in adult patients (age ≥ 18 years) with c-Met+ NSCLC. Later enrollment required presence of an <italic toggle="yes">EGFR</italic>-activating mutation (<italic toggle="yes">EGFR</italic>-M<italic toggle="yes">+</italic>) and progression on a prior EGFR TKI. End points included safety, pharmacokinetics, objective response rate (ORR), and progression-free survival (PFS). The efficacy-evaluable population consisted of c-Met+ patients (confirmed histology [H]-score ≥ 150) who had at least one postbaseline scan; c-Met+ patients with H-scores ≥ 225 were classified as c-Met high.</p>
                </sec>
                <sec>
                  <title>RESULTS</title>
                  <p>As of January 2020, 42 patients were enrolled (N = 36 efficacy-evaluable). Neuropathies were the most common any-grade adverse events reported, with 24 of 42 patients (57%) experiencing at least one event. The pharmacokinetic profile of Teliso-V plus erlotinib was similar to Teliso-V monotherapy. Median PFS for all efficacy-evaluable patients was 5.9 months (95% CI, 2.8 to not reached). ORR for <italic toggle="yes">EGFR</italic>-M<italic toggle="yes">+</italic> patients (n = 28) was 32.1%. Of <italic toggle="yes">EGFR-</italic>M<italic toggle="yes">+</italic> patients, those who were c-Met high (n = 15) had an ORR of 52.6%. Median PFS was 6.8 months for non-T790M+ and for those whose T790M status was unknown, versus 3.7 months for T790M+.</p>
                </sec>
                <sec>
                  <title>CONCLUSION</title>
                  <p>Teliso-V plus erlotinib showed encouraging antitumor activity and acceptable toxicity in EGFR TKI-pretreated patients with <italic toggle="yes">EGFR</italic>-M+, c-Met+ NSCLC.</p>
                </sec>
              </abstract>
              <counts>
                <fig-count count="2"/>
                <table-count count="4"/>
                <equation-count count="0"/>
                <ref-count count="45"/>
                <page-count count="0"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>OPEN-ACCESS</meta-name>
                  <meta-value>TRUE</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="introduction">
              <title>INTRODUCTION</title>
              <p>Non–small-cell lung cancer (NSCLC) represents approximately 85% of all lung cancers and is the leading cause of cancer-related deaths worldwide.<sup><xref rid="b1" ref-type="bibr">1</xref></sup> Unfortunately, most patients diagnosed with NSCLC are affected by advanced-stage disease, conferring a 5-year survival rate as low as 7%.<sup><xref rid="b2" ref-type="bibr">2</xref></sup></p>
              <boxed-text id="B1" position="anchor">
                <sec sec-type="context-box">
                  <title>CONTEXT</title>
                  <p>
                    <list list-type="simple">
                      <list-item>
                        <p>
                          <bold>Key Objective</bold>
                        </p>
                      </list-item>
                      <list-item>
                        <p>Patients diagnosed with advanced non–small-cell lung cancer (NSCLC) have a poor prognosis. Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is common because of the potential acquisition of resistance mutations and/or the aberrant activation of c-Met, a protein that promotes tumor development and progression. This study examined the safety, pharmacokinetics, and preliminary efficacy in patients with c-Met–positive (+) NSCLC treated with the c-Met–targeting drug telisotuzumab vedotin (Teliso-V) in combination with the EGFR TKI erlotinib.</p>
                      </list-item>
                      <list-item>
                        <p>
                          <bold>Knowledge Generated</bold>
                        </p>
                      </list-item>
                      <list-item>
                        <p>Teliso-V plus erlotinib showed encouraging antitumor activity and an acceptable safety profile in EGFR TKI-pretreated patients with <italic toggle="yes">EGFR</italic> mutation (M)+, c-Met+ NSCLC.</p>
                      </list-item>
                      <list-item>
                        <p>
                          <bold>Relevance</bold>
                        </p>
                      </list-item>
                      <list-item>
                        <p>This early-phase trial provides preliminary data on the adverse events and efficacy of an antibody-drug conjugate targeting c-Met, Teliso-V, in combination with erlotinib. The subsets of greatest clinical interest are the patients with <italic toggle="yes">EGFR</italic>-M+ NSCLC who progressed on a prior EGFR TKI, and with high c-Met H-scores by immunohistochemistry. Antibody-drug conjugates are potentially a novel mechanism of targeting <italic toggle="yes">MET</italic> resistance in <italic toggle="yes">EGFR</italic>-M+ NSCLC. Ongoing studies will evaluate the combination of Teliso-V with osimertinib.</p>
                      </list-item>
                    </list>
                  </p>
                </sec>
              </boxed-text>
              <p>c-Met is a transmembrane receptor tyrosine kinase that is encoded by the <italic toggle="yes">MET</italic> proto-oncogene and activated upon binding to the hepatocyte growth factor.<sup><xref rid="b3" ref-type="bibr">3</xref>,<xref rid="b4" ref-type="bibr">4</xref></sup> Dysregulation of c-Met is observed in several types of cancer, including overexpression in approximately 50% of NSCLC.<sup><xref rid="b5" ref-type="bibr">5</xref>-<xref rid="b8" ref-type="bibr">8</xref></sup>
<italic toggle="yes">MET</italic>-based primary driver alterations include <italic toggle="yes">MET</italic> amplification,<sup><xref rid="b9" ref-type="bibr">9</xref></sup>
<italic toggle="yes">MET</italic> exon 14 skipping mutations,<sup><xref rid="b10" ref-type="bibr">10</xref>,<xref rid="b11" ref-type="bibr">11</xref></sup> and <italic toggle="yes">MET</italic> fusions.<sup><xref rid="b12" ref-type="bibr">12</xref></sup>
<italic toggle="yes">MET</italic> amplification can also act as a potential second driver in the setting of acquired resistance to epidermal growth factor receptor (EGFR) inhibitors.<sup><xref rid="b13" ref-type="bibr">13</xref>,<xref rid="b14" ref-type="bibr">14</xref></sup> Overexpression of c-Met overlaps with these genetic <italic toggle="yes">MET</italic> driver and codriver states, but can also exist independently and may provide a target for therapy regardless of the <italic toggle="yes">MET</italic>-signaling addiction of the tumor.<sup><xref rid="b5" ref-type="bibr">5</xref>,<xref rid="b6" ref-type="bibr">6</xref></sup></p>
              <p>Telisotuzumab vedotin (ABBV-399; Teliso-V) is a first-in-class antibody-drug conjugate (ADC) that uses a cleavable linker to combine a recombinant c-Met–targeting humanized monoclonal antibody (ABT-700) and monomethyl auristatin E (MMAE), a potent inhibitor of microtubule polymerization.<sup><xref rid="b15" ref-type="bibr">15</xref></sup> The first-in-human study, to our knowledge, evaluating Teliso-V as monotherapy showed a favorable safety profile and promising antitumor activity in patients with c-Met–overexpressing (c-Met+) NSCLC, and established 2.7 mg/kg dosed once every 21 days (once every 3 weeks; equivalent to one treatment cycle) as the recommended phase two dose (RP2D) and schedule.<sup><xref rid="b16" ref-type="bibr">16</xref></sup></p>
              <p>Originally approved as salvage therapy in unselected patients with NSCLC, the use of EGFR tyrosine kinase inhibitors (TKIs) shifted following the discovery of <italic toggle="yes">EGFR</italic> mutations and their heightened sensitivity to EGFR TKIs.<sup><xref rid="b17" ref-type="bibr">17</xref></sup> Common <italic toggle="yes">EGFR</italic>-activating mutations are exon 19 deletions (del19) and the exon 21 point mutation L858R. Erlotinib, gefitinib, afatinib, and osimertinib are all licensed for first-line treatment of tumors harboring these common mutations.<sup><xref rid="b18" ref-type="bibr">18</xref>-<xref rid="b23" ref-type="bibr">23</xref></sup> Afatinib is also licensed to treat uncommon <italic toggle="yes">EGFR</italic> mutations such as S768I, L861Q, and G719.<sup><xref rid="b20" ref-type="bibr">20</xref></sup></p>
              <p>Acquired resistance to first- and second-generation EGFR TKIs most frequently occurs via acquisition of the T790M <italic toggle="yes">EGFR</italic> mutation,<sup><xref rid="b13" ref-type="bibr">13</xref>,<xref rid="b14" ref-type="bibr">14</xref>,<xref rid="b24" ref-type="bibr">24</xref></sup> but can also occur through aberrant c-Met activation, with the frequency varying by whether resistance emerges on a first-/second- versus a third-generation EGFR TKI.<sup><xref rid="b24" ref-type="bibr">24</xref>-<xref rid="b28" ref-type="bibr">28</xref></sup></p>
              <p>Herein, we report on a phase Ib study evaluating dual targeting of c-Met and EGFR via combination therapy with Teliso-V plus erlotinib in patients with c-Met+ NSCLC, focusing primarily on the <italic toggle="yes">EGFR</italic> mutation-positive (<italic toggle="yes">EGFR</italic>-M<italic toggle="yes">+</italic>) post-EGFR TKI–treated population.</p>
            </sec>
            <sec sec-type="patients|methods">
              <title>PATIENTS AND METHODS</title>
              <sec>
                <title>Study Design and Treatment</title>
                <p>This was a phase I/Ib multicenter, open-label study (ClinicalTrials.gov identifier: <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT02099058" ext-link-type="uri">NCT02099058</ext-link>) evaluating Teliso-V plus erlotinib (150 mg orally once daily) in patients with advanced c-Met+ NSCLC. All enrolled patients received the RP2D of 2.7 mg/kg Teliso-V intravenously once every 3 weeks.<sup><xref rid="b29" ref-type="bibr">29</xref></sup> A subset of patients (n = 3) was enrolled in a safety lead-in cohort (2.4 mg/kg Teliso-V once every 3 weeks) to assess the safety of this drug combination before escalating to the RP2D; these patients were included in the safety assessment.</p>
                <p>Patients could receive study treatment until disease progression, death, or withdrawal of consent. Patients who discontinued erlotinib because of toxicity unrelated to Teliso-V could continue Teliso-V monotherapy. Detailed dose-modification guidelines are provided in the study Protocol (online only). Briefly, protocol-mandated dose interruptions were required for grade 3 neuropathies, or grades 3/4 neutropenia, until the adverse event (AE) improved to grade ≤ 2. Study discontinuation criteria were met after three dose reductions or a dose interruption of &gt; 21 days (or &gt; 42 days for neuropathy).</p>
                <p>The study was conducted in accordance with the protocol, the International Conference on Harmonization, Good Clinical Practice Guidelines, and the Declaration of Helsinki. All patients provided written informed consent; the study was approved by the local ethics committee/institutional review board.</p>
              </sec>
              <sec sec-type="subjects">
                <title>Patient Population</title>
                <p>This study enrolled adult patients (age ≥ 18 years) with advanced NSCLC (measurable per Response Evaluation Criteria in Solid Tumors v1.1) not amenable to resection or other approved therapies. Patients were required to have archival tumor tissue available for biomarker analysis and confirmation of c-Met overexpression, <italic toggle="yes">MET</italic> exon 14 skipping mutations, or <italic toggle="yes">MET</italic> amplification, as determined by a central/local site laboratory. Samples could have been collected at any point in the patient's prior treatment journey. Although not initially required, later study protocol amendments required the patient's tumor to have a del19 or L858R <italic toggle="yes">EGFR</italic>-activating mutation and to have previously progressed on an EGFR TKI. Patients must have had an Eastern Cooperative Oncology Group performance status of 0-2 and adequate bone marrow, renal, and hepatic function. Main exclusion criteria included any prior anticancer therapy, uncontrolled central nervous system metastases, or any medical condition that would put the patient at an unacceptably high risk for toxicity.</p>
              </sec>
              <sec>
                <title>Assessments</title>
                <sec>
                  <title>
Pharmacokinetics.
</title>
                  <p>Detailed methodology on pharmacokinetic analysis can be found in the Data Supplement (online only).</p>
                </sec>
                <sec>
                  <title>
Safety.
</title>
                  <p>AEs were assessed throughout the study and for 60 days following discontinuation of study treatment. AEs were reported by site using Medical Dictionary for Regulatory Activities system organ class preferred terms as determined by the site investigator; multiple similar terms could be used to describe the same event in a single patient. AE severity was graded according to National Cancer Institute Common Terminology Criteria for Adverse Events v4.03.</p>
                  <p>The safety analysis population included all patients who received any amount of study drug. Safety summaries were descriptive only, and no statistical inference was performed.</p>
                </sec>
                <sec>
                  <title>
Efficacy.
</title>
                  <p>Radiographic tumor assessments (via computed tomography or magnetic resonance imaging) were performed within 28 days of treatment initiation and once every 6 weeks thereafter until documented disease progression, start of new anticancer therapy, death, or withdrawal of consent. Responses were assessed according to Response Evaluation Criteria in Solid Tumors v1.1. Efficacy end points included objective response rate (ORR) and progression-free survival (PFS).</p>
                  <p>ORR was defined as the proportion of patients with confirmed complete response (CR) or partial response (PR). Disease control rate (DCR) was defined as the proportion of patients with confirmed CR, PR, or stable disease (SD; sustained for a minimum 6 weeks). PFS was defined as the time from the first dose of study drug to either the first date of documented disease progression, or death, whichever occurred first, or at the date of last disease assessment. Patients with no tissue available for H-score assessment, or those with H-score &lt; 150, were not included in the efficacy analysis.</p>
                </sec>
                <sec>
                  <title>
Biomarker analysis.
</title>
                  <p>Detailed methodology on biomarker analysis can be found in the Data Supplement. Briefly, archived or newly acquired tumor tissue was analyzed for c-Met protein expression by immunohistochemistry. c-Met–overexpressing tumors were defined as H-score ≥ 150 (c-Met+); this threshold was chosen by the sponsor (AbbVie, North Chicago, IL) to enrich for patients most likely to benefit from Teliso-V, as preclinical studies have shown that some level of c-Met expression is needed for Teliso-V efficacy.<sup><xref rid="b15" ref-type="bibr">15</xref></sup> Tumors with H-score ≥ 225 were defined as c-Met high, as previous clinical studies noted that this higher threshold of expression enriched for antitumor responses.<sup><xref rid="b29" ref-type="bibr">29</xref></sup></p>
                </sec>
                <sec>
                  <title>
Statistical analysis.
</title>
                  <p>A sample size of 40 patients with c-Met+ NSCLC was estimated to provide 80% power to detect an absolute improvement in ORR from 10% to 25%, with a 10% two-sided significance level.</p>
                  <p>ORR was assessed using the two-sided 95% CIs provided by the Clopper-Pearson (exact) method. PFS was summarized by Kaplan-Meier estimates, and median PFS was calculated with two-sided 95% CIs.</p>
                </sec>
              </sec>
            </sec>
            <sec sec-type="results">
              <title>RESULTS</title>
              <sec sec-type="subjects">
                <title>Patient Characteristics</title>
                <p>Between April 2015 and January 2020, 42 patients were enrolled in the cohort evaluating the combination of Teliso-V plus erlotinib. Patients who either did not have tumor tissue available for H-score assessment or had H-score &lt; 150 (n = 6) were not included in the efficacy set (N = 36). A subset of patients (n = 8) was enrolled before the amendment restricting enrollment to <italic toggle="yes">EGFR</italic> L858R or del19 was added. Five of these eight patients had an unaltered <italic toggle="yes">EGFR</italic> gene (<italic toggle="yes">EGFR-</italic>wild-type [WT]), and three had either rare (L861Q or L861R) or unknown <italic toggle="yes">EGFR</italic> mutations. Baseline demographics of the c-Met+ efficacy-evaluable population are summarized in Table <xref rid="tbl1" ref-type="table">1</xref>. Importantly, 53% were c-Met high (H-score ≥ 225). <italic toggle="yes">MET</italic> amplification was found in six patients (17%): four <italic toggle="yes">EGFR</italic>-M<italic toggle="yes">+</italic>, one <italic toggle="yes">EGFR</italic>-WT, and one rare/unknown <italic toggle="yes">EGFR</italic>. Of the six <italic toggle="yes">MET</italic>-amplified patients, five were c-Met high. Patients with confirmed T790M mutations (n = 13) were split evenly between c-Met high (n = 6) and lower c-Met expression (n = 7).</p>
                <table-wrap position="float" id="tbl1">
                  <label>TABLE 1.</label>
                  <caption>
                    <p>Demographics and Baseline Clinical Characteristics (Efficacy-Evaluable Population)</p>
                  </caption>
                  <graphic xlink:href="jco-41-1105-g001" position="float"/>
                </table-wrap>
                <p>Twenty-five of 36 efficacy-evaluable patients (69%) had received three or more prior lines of therapy. Thirty of 36 patients (83%) received a first-/second-generation EGFR TKI across all lines, and 16 patients (44%) received a third-generation EGFR TKI. In 33%, a third-generation EGFR TKI was their last prior therapy.</p>
              </sec>
              <sec>
                <title>Safety</title>
                <p>All patients experienced one or more AE (Table <xref rid="tbl2" ref-type="table">2</xref>). The most common any-grade AEs were peripheral sensory neuropathy (43%), dermatitis acneiform (38%), diarrhea (33%), and hypoalbuminemia (33%). Grade ≥ 3 AEs occurred in 27 patients (64%); most common were pulmonary embolism (PE) (14%), hypokalemia (10%), and diarrhea, malignant neoplasm progression, peripheral sensory neuropathy, and hypophosphatemia (7% each). Any-grade AEs deemed possibly related to Teliso-V (treatment-related AEs) were observed in 37 patients (88%), the most common being peripheral sensory neuropathy (36%) and peripheral neuropathy (19%; Data Supplement).</p>
                <table-wrap position="float" id="tbl2">
                  <label>TABLE 2.</label>
                  <caption>
                    <p>Adverse Events</p>
                  </caption>
                  <graphic xlink:href="jco-41-1105-g002" position="float"/>
                </table-wrap>
                <p>Grade ≥ 3 treatment-related AEs occurred in 13 patients (31%); the most frequently occurring were hypophosphatemia and peripheral sensory neuropathy (7% each; Data Supplement). Serious AEs (≥ 5% of patients) were malignant neoplasm progression (7%), and pneumonia, dehydration, and PE (5% each; Data Supplement). Three of 42 patients (7%) reported ≥ 1 serious AE deemed possibly related to Teliso-V: decreased appetite, dehydration, hemoptysis, peripheral neuropathy, and pneumonia (2% each).</p>
                <p>Twenty-four of 42 patients (57%) reported at least one event falling into the peripheral neuropathy Standardized Medical Dictionary for Regulatory Activities Queries. There were 32 any-grade neuropathy-type events reported in these 24 patients, with peripheral sensory neuropathy the most common (18/32). These events were mostly low grade, with five events of grade ≥ 3 (three peripheral sensory neuropathy, one peripheral sensorimotor neuropathy, and one peripheral neuropathy). Median time to first onset of any event from the peripheral neuropathy Standardized Medical Dictionary for Regulatory Activities Queries was 72.5 days (range, 5-197 days). The most common AE leading to study drug reductions, interruptions, or discontinuations was peripheral sensory neuropathy (10%, 21%, and 21%, respectively; Data Supplement). Death due to AEs occurred in three patients (7%), resulting from one case of hemoptysis (2%) that was deemed possibly related to Teliso-V, and two cases (5%) of malignant neoplasm progression (Data Supplement).</p>
              </sec>
              <sec>
                <title>Pharmacokinetics</title>
                <p>The preliminary pharmacokinetic parameters for Teliso-V conjugate in the patients who received Teliso-V plus erlotinib at 2.7 mg/kg once every 3 weeks are summarized in the Data Supplement. The estimated half-life was approximately 3 days. Teliso-V concentrations peaked immediately postinfusion (time to C<sub>max</sub> [maximum observed plasma concentration]; ≈ 1 hour), with geometric mean (%CV) C<sub>max</sub> of 57.0 μg/mL (21%) and area under the concentration-time curve from time zero to infinity (%CV) of 4,048 μg h/mL (17%).</p>
              </sec>
              <sec>
                <title>Efficacy</title>
                <p>Median duration of exposure to Teliso-V was 18.1 weeks (range, 3.1-99.1 weeks), and patients received a median seven treatment cycles (range, 2.0-34.0 cycles). Median duration of exposure to erlotinib was 20.3 weeks (range, 3.1-110.4 weeks), with patients receiving a median five-and-a-half treatment cycles (range, 2.0-33.0 cycles).</p>
                <p>Efficacy results are summarized in Table <xref rid="tbl3" ref-type="table">3</xref>. ORR for all efficacy-evaluable patients was 30.6% (11/36; 95% CI, 16.3 to 48.1), and DCR was 86.1% (31/36; 95% CI, 70.5 to 95.3). Median PFS for all efficacy-evaluable patients was 5.9 months (95% CI, 2.8 to not reached [NR]). Duration of response was NR at the time of data cutoff.</p>
                <table-wrap position="float" id="tbl3">
                  <label>TABLE 3.</label>
                  <caption>
                    <p>Efficacy Summary</p>
                  </caption>
                  <graphic xlink:href="jco-41-1105-g003" position="float"/>
                </table-wrap>
                <p>For <italic toggle="yes">EGFR</italic>-M<italic toggle="yes">+</italic> patients (n = 28), ORR was 32.1% (9/28; 95% CI, 15.9 to 52.4), with one CR (3.6%) and eight PR (28.6%). DCR was 85.7% (24/28; 95% CI, 67.3 to 96.0) and median PFS was 5.9 months (95% CI, 2.8 to NR; Table <xref rid="tbl3" ref-type="table">3</xref>, Fig <xref rid="fig1" ref-type="fig">1</xref>A). In an exploratory ad hoc subgroup analysis of <italic toggle="yes">EGFR</italic>-M+ patients by T790M status (n = 13 T790M<italic toggle="yes">+ v</italic> n = 15 non-T790M<italic toggle="yes">+</italic>), ORR and DCR were 31% and 77%, respectively, in T790M<italic toggle="yes">+</italic>, and 33% and 93%, respectively, in non-T790M<italic toggle="yes">+</italic> patients (Table <xref rid="tbl4" ref-type="table">4</xref>). Median PFS was 3.7 months (95% CI, 1.4 to NR) for T790M<italic toggle="yes">+</italic> patients, compared with 6.8 months (95% CI, 4.3 to NR) for non-T790M<italic toggle="yes">+</italic> patients (Fig <xref rid="fig1" ref-type="fig">1</xref>B).</p>
                <fig position="float" id="fig1" fig-type="figure">
                  <label>FIG 1.</label>
                  <caption>
                    <p>Kaplan-Meier estimates of progression-free survival in (A) the efficacy-evaluable population stratified by <italic toggle="yes">EGFR</italic> mutation status and (B) the subset of patients classified as <italic toggle="yes">EGFR</italic>-M<italic toggle="yes">+</italic> with confirmed T790M resistance status. EGFR, epidermal growth factor receptor; <italic toggle="yes">EGFR</italic>-M<italic toggle="yes">+</italic>, <italic toggle="yes">EGFR</italic> mutation-positive (del19, L858R); <italic toggle="yes">EGFR</italic>-WT, <italic toggle="yes">EGFR</italic> mutation wild-type; NR, not reached; PFS, progression-free survival.</p>
                  </caption>
                  <graphic xlink:href="jco-41-1105-g004" position="float"/>
                </fig>
                <table-wrap position="float" id="tbl4">
                  <label>TABLE 4.</label>
                  <caption>
                    <p>Exploratory Subgroup Analysis</p>
                  </caption>
                  <graphic xlink:href="jco-41-1105-g005" position="float"/>
                </table-wrap>
                <p>ORR in <italic toggle="yes">EGFR</italic>-M<italic toggle="yes">+</italic> patients who had previously received the third-generation EGFR TKI osimertinib (n = 15) was 27% (4/15). ORR was 39% (5/13) in <italic toggle="yes">EGFR</italic>-M<italic toggle="yes">+</italic> patients who had never received osimertinib. DCR was 100% (13/13) for those with no prior exposure to osimertinib compared with 73.3% (11/15) for those who had prior exposure (Table <xref rid="tbl4" ref-type="table">4</xref>). ORR in <italic toggle="yes">EGFR</italic>-WT patients (n = 5) was 40% (2/5; two PR) and DCR was 80% (4/5; two PR and two SD). All three patients with rare/unknown <italic toggle="yes">EGFR</italic> mutations achieved SD.</p>
                <p>Figure <xref rid="fig2" ref-type="fig">2</xref> shows best percentage change from baseline in target lesions. Among patients with c-Met–high scores (n = 19), one achieved a CR (1/19; 5.3%; <italic toggle="yes">EGFR</italic>-M<italic toggle="yes">+</italic>), nine achieved a PR (9/19; 47.4%; six <italic toggle="yes">EGFR</italic>-M<italic toggle="yes">+</italic> and three <italic toggle="yes">EGFR</italic>-WT), five had SD (5/19; 26.3%; <italic toggle="yes">EGFR</italic>-M<italic toggle="yes">+</italic>), and four experienced progressive disease (4/19; 21.1%; three <italic toggle="yes">EGFR</italic>-M<italic toggle="yes">+</italic> and one rare/unknown <italic toggle="yes">EGFR</italic>), indicating an ORR of 52.6% and DCR of 78.9%. No patients with lower c-Met scores achieved a CR; two of 16 had a PR (12.5%), 12 had SD (75%), and two had progressive disease (12.5%), indicating an ORR of 12.5% and DCR of 87.5%. Of note, five of six <italic toggle="yes">MET-</italic>amplified patients were also c-Met high. Of these, three of five achieved a PR (60%) and two had SD (50%), indicating a DCR of 100%. The one <italic toggle="yes">MET</italic>-amplified patient with a lower c-Met score achieved SD. Most responses were achieved by the first post-treatment scan (Data Supplement).</p>
                <fig position="float" id="fig2" fig-type="figure">
                  <label>FIG 2.</label>
                  <caption>
                    <p>Best percentage reduction in target lesions from baseline in patients receiving Teliso-V plus erlotinib. Asterisks indicate <italic toggle="yes">MET</italic>-amplified patients (n = 6). HI indicates c-Met high (≥ 225; n = 19). CR, complete response; EGFR, epidermal growth factor receptor; <italic toggle="yes">EGFR</italic>-M<italic toggle="yes">+</italic>, <italic toggle="yes">EGFR</italic> mutation-positive; <italic toggle="yes">EGFR</italic>-WT, <italic toggle="yes">EGFR</italic> mutation wild-type; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.</p>
                  </caption>
                  <graphic xlink:href="jco-41-1105-g006" position="float"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="discussion">
              <title>DISCUSSION</title>
              <p>Teliso-V plus erlotinib had an acceptable safety profile in patients with c-Met+ NSCLC. Importantly, the addition of erlotinib to Teliso-V produced no unexpected safety signals, and the pharmacokinetic profile was similar to that observed with Teliso-V monotherapy.<sup><xref rid="b16" ref-type="bibr">16</xref></sup> This combination also showed promising efficacy, especially in c-Met–high <italic toggle="yes">EGFR</italic>-M<italic toggle="yes">+</italic> patients, in agreement with each drug's mechanism of action.</p>
              <p>The most frequent AE observed in this study was neuropathy (any kind; 57%; Table <xref rid="tbl2" ref-type="table">2</xref>), a known side effect of MMAE-containing drugs.<sup><xref rid="b30" ref-type="bibr">30</xref></sup> Although 11 patients (26%) required dose interruption or discontinuation of Teliso-V because of neuropathy, most of these events were mild-to-moderate (only 12% grade ≥ 3). The rate of peripheral sensory neuropathy in this study (43%) was similar to that observed with other approved MMAE ADC-containing drugs.<sup><xref rid="b31" ref-type="bibr">31</xref>-<xref rid="b34" ref-type="bibr">34</xref></sup> Of note, 86% of patients in this study had received prior chemotherapy and several had prior history of neuropathy, both of which are risk factors for development of subsequent neuropathy.<sup><xref rid="b35" ref-type="bibr">35</xref></sup></p>
              <p>Ocular toxicities affecting the cornea are also associated with the use of MMAE ADCs and erlotinib,<sup><xref rid="b17" ref-type="bibr">17</xref>,<xref rid="b18" ref-type="bibr">18</xref>,<xref rid="b36" ref-type="bibr">36</xref>,<xref rid="b37" ref-type="bibr">37</xref></sup> with incidence rates as high as 46%-77% for some approved drugs.<sup><xref rid="b32" ref-type="bibr">32</xref>,<xref rid="b38" ref-type="bibr">38</xref></sup> Grade 1-2 keratitis was reported in 14% of patients in this study (Table <xref rid="tbl2" ref-type="table">2</xref>); however, no patients experienced grade ≥ 3 keratitis. Incidence rates of all other ocular toxicities were ≤ 5% for patients treated with Teliso-V plus erlotinib, well below the rates reported for other approved MMAE ADC-containing drugs.</p>
              <p>Additionally, patients in this study displayed some toxicities associated with targeting c-Met,<sup><xref rid="b39" ref-type="bibr">39</xref>,<xref rid="b40" ref-type="bibr">40</xref></sup> including peripheral edema (12%) and hypoalbuminemia (33%). However, similar to Teliso-V monotherapy, no patients experienced grade ≥ 3 peripheral edema or hypoalbuminemia.<sup><xref rid="b16" ref-type="bibr">16</xref></sup> Altogether, this suggests that the addition of erlotinib did not exacerbate the safety profile of Teliso-V.</p>
              <p>AEs associated with use of erlotinib, most notably skin toxicities, have been previously reported.<sup><xref rid="b18" ref-type="bibr">18</xref>,<xref rid="b41" ref-type="bibr">41</xref>,<xref rid="b42" ref-type="bibr">42</xref></sup> Skin-related AEs were also reported in our study, including dermatitis acneiform (38%). Although our sample is small, this rate is higher than that reported for erlotinib monotherapy. Importantly, most AEs of dermatitis acneiform in this study were low grade (2 grade ≥ 3). Notably, more than half of the patients enrolled in this study had received three or more prior lines of EGFR TKI therapy, and consequently may have become hypersensitized to EGFR TKI-mediated skin toxicity.</p>
              <p>There were six events of PE in our study, all of which were grade ≥ 3. However, none of these events were deemed by investigators as related to Teliso-V. It is important to note that the patients in this study were in generally poor health with heavily pretreated metastatic lung cancer, thus putting them at increased risk for high-grade pulmonary events. Previous clinical studies of Teliso-V monotherapy<sup><xref rid="b16" ref-type="bibr">16</xref>,<xref rid="b29" ref-type="bibr">29</xref></sup> reported fewer PE AEs, and it cannot be excluded that the observations made here are related to the combination of Teliso-V plus erlotinib. Further studies with larger data sets are needed to understand this potential relationship.</p>
              <p>Promising antitumor activity was observed with Teliso-V plus erlotinib in this heavily pretreated population, including almost 50% who had previously received three or more lines of EGFR TKI treatment. Despite these demographics, the ORR and DCR were 30.6% and 86.1%, respectively, in the overall efficacy set, demonstrating an improvement over Teliso-V monotherapy (ORR, 18.8%; DCR, 56.3%),<sup><xref rid="b16" ref-type="bibr">16</xref></sup> and 32.1% and 85.7%, respectively, for the <italic toggle="yes">EGFR</italic>-M+ group.</p>
              <p>We cannot rule out the possibility that the antitumor activity reported in our study is driven by Teliso-V alone, as most <italic toggle="yes">EGFR</italic>-M<italic toggle="yes">+</italic> patients had received one or more prior line of TKI therapy, which often leads to acquired resistance to subsequent EGFR-targeted therapies.<sup><xref rid="b13" ref-type="bibr">13</xref>,<xref rid="b14" ref-type="bibr">14</xref>,<xref rid="b24" ref-type="bibr">24</xref></sup> Indeed, 46% of <italic toggle="yes">EGFR</italic>-M<italic toggle="yes">+</italic> patients in our study were T790M+, a known acquired mutation conferring resistance to first-/second-generation EGFR TKIs. Here, we report that median PFS for non-T790M<italic toggle="yes">+</italic> patients was higher (6.8 months) compared with T790M<italic toggle="yes">+</italic> patients (3.7 months), suggesting that non-T790M<italic toggle="yes">+</italic> patients derived greater benefit from the combination of Teliso-V plus erlotinib.</p>
              <p>Patients in the efficacy-evaluable cohort of this study were all c-Met+ as defined by H-score ≥ 150. However, levels of c-Met overexpression within the tumor varied among patients, and response rates were higher in tumors with higher H-scores. This observation is in line with the proposed mechanism of action of Teliso-V, whereby internalization of Teliso-V bound to c-Met allows for the intracellular release of the MMAE toxin. Other studies have proposed targeting both EGFR and c-Met using TKIs against both receptors.<sup><xref rid="b40" ref-type="bibr">40</xref>,<xref rid="b43" ref-type="bibr">43</xref>,<xref rid="b44" ref-type="bibr">44</xref></sup> One key difference with our study is that to respond to a c-Met TKI, tumors must be addicted to c-Met signaling, which requires a genetic alteration such as <italic toggle="yes">MET-</italic>amplification or a <italic toggle="yes">MET</italic> exon14 skipping mutation.<sup><xref rid="b5" ref-type="bibr">5</xref>,<xref rid="b6" ref-type="bibr">6</xref></sup> Here, we were able to target both <italic toggle="yes">MET</italic>-amplified (17%) as well as c-Met+ but nonamplified tumors (78%), possibly expanding the patient population that could benefit from this combination compared with a combination of TKIs. Interestingly, the <italic toggle="yes">MET</italic>-amplified patient subset responded particularly well to Teliso-V plus erlotinib, with an ORR of 62.5% and a DCR of 100%. Of the five patients who were c-Met high and <italic toggle="yes">MET</italic>-amplified, the ORR was 60% (three PR) and the DCR was 100% (three PR and two SD). These results could indicate that <italic toggle="yes">MET</italic>-amplified tumors have higher levels of c-Met protein expression, that Teliso-V also exercises a c-Met signaling inhibition effect in addition to its direct cell killing effect, or both.</p>
              <p>Predefining c-Met+ as H-score ≥ 150 is a limitation of this study, as this threshold was determined on the basis of preclinical data and may not represent the most appropriate threshold.<sup><xref rid="b9" ref-type="bibr">9</xref></sup> Additionally, assessment of c-Met expression was determined on the basis of tissue obtained at any time before enrollment, including archival tissue, and c-Met levels could have changed during the period between tissue collection and study enrollment. The use of archival tissue also hampered assessment of <italic toggle="yes">MET</italic> amplification and <italic toggle="yes">MET</italic> exon 14 skipping mutation status, as not all patients had sufficient tissue available for testing.</p>
              <p>Additionally, several <italic toggle="yes">EGFR</italic>-WT patients were enrolled, and some activity was seen in these patients (ORR, 40%; DCR, 80%). This activity could be due to Teliso-V alone, as patients with <italic toggle="yes">EGFR</italic>-WT tumors are unlikely to benefit from erlotinib therapy. The antitumor activity of Teliso-V monotherapy in <italic toggle="yes">EGFR</italic>-WT patients is currently being explored in the LUMINOSITY clinical trial (ClinicalTrials.gov identifier: <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT03539536" ext-link-type="uri">NCT03539536</ext-link>).</p>
              <p>Osimertinib has now displaced prior-generation agents as first-line treatment because of the improvements in overall survival and PFS observed in the phase III FLAURA study (ClinicalTrials.gov identifier: <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT02296125" ext-link-type="uri">NCT02296125</ext-link>),<sup><xref rid="b27" ref-type="bibr">27</xref>,<xref rid="b28" ref-type="bibr">28</xref></sup> as well as its activity against T790M<italic toggle="yes">+</italic> tumors (reviewed in Gao et al<sup><xref rid="b45" ref-type="bibr">45</xref></sup>). As such, the combination of Teliso-V plus osimertinib is now being explored in a phase I study (ClinicalTrials.gov identifier: <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT02099058" ext-link-type="uri">NCT02099058</ext-link>).<sup><xref rid="b9" ref-type="bibr">9</xref></sup></p>
              <p>In conclusion, the combination of Teliso-V plus erlotinib showed an acceptable safety profile and encouraging antitumor activity in heavily pretreated patients, especially in <italic toggle="yes">EGFR</italic>-M<italic toggle="yes">+</italic> c-Met+ NSCLC in which previous EGFR TKIs failed. Although exploratory, targeting c-Met and <italic toggle="yes">EGFR</italic> showed promising results in this underserved patient population and is worthy of further evaluation in larger studies. Our data also support additional prospective investigations of Teliso-V in combination with osimertinib in selected patient populations.</p>
            </sec>
          </body>
          <back>
            <ack>
              <title>ACKNOWLEDGMENT</title>
              <p>AbbVie and the authors thank all the trial investigators and the patients who participated in this clinical trial. Medical writing support was provided by Rebecca L. Crepeau, PhD, from Aptitude Health, Atlanta, GA, and funded by AbbVie.</p>
            </ack>
            <fn-group>
              <fn fn-type="other">
                <p>See accompanying article on page <related-article related-article-type="companion" ext-link-type="doi" id="ra1" xlink:href="10.1200/JCO.22.02086">1129</related-article></p>
              </fn>
            </fn-group>
            <fn-group content-type="presented-at">
              <title>PRIOR PRESENTATION</title>
              <fn specific-use="presented-at" fn-type="presented-at">
                <p>Presented in part at the European Society for Medical Oncology (ESMO) Annual Meeting, Munich, Germany, October 19-23, 2018; and at the ASCO Annual Meeting, Chicago, IL, May 31-June 4, 2019.</p>
              </fn>
            </fn-group>
            <fn-group content-type="supported-by">
              <title>SUPPORT</title>
              <fn specific-use="supported-by" fn-type="supported-by">
                <p>Supported by AbbVie, Inc, which funded this study and participated in the study design, research, analysis, data collection, interpretation of data, review, and approval of the publication. ABBV-399 uses ABT-700, an antibody licensed from Pierre Fabre, and antibody-drug conjugate technology licensed from Seattle Genetics. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship.</p>
              </fn>
            </fn-group>
            <fn-group content-type="trial">
              <title>CLINICAL TRIAL INFORMATION</title>
              <fn specific-use="trial" fn-type="other">
                <p>
                  <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT02099058" ext-link-type="uri">NCT02099058</ext-link>
                </p>
              </fn>
            </fn-group>
            <sec sec-type="data-availability">
              <title>DATA SHARING STATEMENT</title>
              <p>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (eg, Protocols and Clinical Study Reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</p>
              <p>These clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link: <ext-link xlink:href="https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html" ext-link-type="uri">https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ext-link>.</p>
            </sec>
            <sec sec-type="contributed">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p><bold>Conception and design:</bold> Everett Vokes, Monica Motwani, Martin Dunbar, Apurvasena Parikh, Vincent Blot, Jun Wu</p>
              <p><bold>Provision of study materials or patients:</bold> D. Ross Camidge, Fabrice Barlesi, Jonathan W. Goldman, Daniel Morgensztern, Rebecca Heist, Alex Spira, Eric Angevin, David S. Hong</p>
              <p><bold>Collection and assembly of data:</bold> D. Ross Camidge, Jonathan W. Goldman, Daniel Morgensztern, Rebecca Heist, Everett Vokes, Alex Spira, Eric Angevin, Wu-Chou Su, David S. Hong, John H. Strickler, Monica Motwani, Apurvasena Parikh, Vincent Blot, Jun Wu, Karen Kelly</p>
              <p><bold>Data analysis and interpretation:</bold> Fabrice Barlesi, Jonathan W. Goldman, Daniel Morgensztern, Rebecca Heist, Everett Vokes, Eric Angevin, David S. Hong, Monica Motwani, Martin Dunbar, Apurvasena Parikh, Elysa Noon, Vincent Blot, Jun Wu, Karen Kelly</p>
              <p><bold>Manuscript writing:</bold> All authors</p>
              <p><bold>Final approval of manuscript:</bold> All authors</p>
              <p><bold>Accountable for all aspects of the work:</bold> All authors</p>
            </sec>
            <sec sec-type="disclosures">
              <title>AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</title>
              <sec>
                <title>Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer</title>
                <p>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to <ext-link xlink:href="http://www.asco.org/rwc" ext-link-type="uri">www.asco.org/rwc</ext-link> or <ext-link xlink:href="https://ascopubs.org/jco/authors/author-center" ext-link-type="uri">ascopubs.org/jco/authors/author-center</ext-link>.</p>
                <p>Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (<ext-link xlink:href="https://openpaymentsdata.cms.gov/" ext-link-type="uri">Open Payments</ext-link>).</p>
                <fn-group content-type="COI-statement">
                  <fn id="con1" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>D. Ross Camidge</bold>
                    </p>
                    <p><bold>Honoraria:</bold> Roche, Takeda, AstraZeneca, Daiichi Sankyo, Bio-Thera, Ribon Therapeutics, AbbVie, Apollomics, Elevation Oncology, EMD Serono, Helsinn Therapeutics, Lilly, Nuvalent, Inc, Seattle Genetics, Kestrel Labs, Amgen Astellas BioPharma, Janssen, OnKure, Mersana, Sanofi, Anheart Therapeutics, BeiGene, Hengrui Pharmaceutical, Puma Biotechnology, Turning Point Therapeutics, BeiGene, Dizal Pharma, Hummingbird, Mirati Therapeutics, Nalo</p>
                    <p><bold>Research Funding:</bold> Inivata (Inst)</p>
                  </fn>
                  <fn id="con2" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Wu-Chou Su</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> Bayer Schering Pharma, MSD Oncology, Lilly, Merck</p>
                  </fn>
                  <fn id="con3" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Jun Wu</bold>
                    </p>
                    <p><bold>Employment:</bold> AbbVie</p>
                    <p><bold>Stock and Other Ownership Interests:</bold> AbbVie</p>
                  </fn>
                  <fn id="con4" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Jonathan W. Goldman</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> AstraZeneca, Bristol Myers Squibb, Lilly, Amgen, Pfizer</p>
                    <p><bold>Research Funding:</bold> Lilly (Inst), Genentech/Roche (Inst), Bristol Myers Squibb (Inst), AstraZeneca/MedImmune (Inst), Array BioPharma (Inst), AbbVie (Inst), Corvus Pharmaceuticals (Inst), Spectrum Pharmaceuticals (Inst), Advaxis (Inst), Pfizer (Inst)</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> AstraZeneca</p>
                    <p>
                      <bold>Open Payments Link:</bold>
                      <ext-link xlink:href="https://openpaymentsdata.cms.gov/physician/124819" ext-link-type="uri">https://openpaymentsdata.cms.gov/physician/124819</ext-link>
                    </p>
                  </fn>
                  <fn id="con5" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>John H. Strickler</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> Bayer, Natera (Inst), Pfizer, Mereo Biopharma, AstraZeneca, Viatris, Seattle Genetics, Roche/Genentech (Inst), Inivata, Silverback Therapeutics, GlaxoSmithKline, Pionyr, AbbVie, Takeda, Zentalis</p>
                    <p><bold>Research Funding:</bold> AbbVie (Inst), Roche/Genentech (Inst), Leap Therapeutics (Inst), Nektar (Inst), Amgen (Inst), Curegenix (Inst), A*STAR (Inst), Bayer (Inst), AstraZeneca/MedImmune (Inst), Sanofi (Inst), Daiichi Sankyo/Lilly, Silverback Therapeutics (Inst), Erasca, Inc (Inst), Seattle Genetics (Inst)</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Guardant Health, Seattle Genetics</p>
                  </fn>
                  <fn id="con6" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Eric Angevin</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> MedImmune, Celgene, GlaxoSmithKline, Merck Sharp &amp; Dohme, Roche</p>
                    <p><bold>Research Funding:</bold> AbbVie, Pfizer, GlaxoSmithKline, Sanofi, MedImmune, Octimet</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Innate Pharma, Celgene, GlaxoSmithKline, AbbVie, Bristol Myers Squibb, AstraZeneca</p>
                  </fn>
                  <fn id="con7" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Vincent Blot</bold>
                    </p>
                    <p><bold>Employment:</bold> AbbVie</p>
                    <p><bold>Stock and Other Ownership Interests:</bold> AbbVie</p>
                    <p><bold>Research Funding:</bold> AbbVie</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> AbbVie</p>
                  </fn>
                  <fn id="con8" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Rebecca Heist</bold>
                    </p>
                    <p><bold>Honoraria:</bold> Chugai/Roche</p>
                    <p><bold>Consulting or Advisory Role:</bold> Novartis, Daichii Sankyo, EMD Serono/Merck, AbbVie</p>
                    <p><bold>Research Funding:</bold> AbbVie (Inst), Novartis (Inst), Roche (Inst), Incyte (Inst), Celgene (Inst), Mirati Therapeutics (Inst), Peregrine Pharmaceuticals (Inst), Exelixis (Inst), Millennium (Inst), Debiopharm Group (Inst), Corvus Pharmaceuticals (Inst), Daiichi Sankyo (Inst), Agios (Inst), Exelixis (Inst), Pfizer (Inst), Lilly (Inst), Turning Point Therapeutics (Inst)</p>
                  </fn>
                  <fn id="con9" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Martin Dunbar</bold>
                    </p>
                    <p><bold>Employment:</bold> AbbVie</p>
                    <p><bold>Stock and Other Ownership Interests:</bold> AbbVie</p>
                  </fn>
                  <fn id="con10" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Alex Spira</bold>
                    </p>
                    <p><bold>Leadership:</bold> Next Oncology (Inst)</p>
                    <p><bold>Stock and Other Ownership Interests:</bold> Lilly</p>
                    <p><bold>Honoraria:</bold> CytomX Therapeutics, AstraZeneca/MedImmune, Merck, Takeda, Amgen, Janssen Oncology, Novartis, Bristol Myers Squibb, Bayer</p>
                    <p><bold>Consulting or Advisory Role:</bold> Array BioPharma (Inst), Incyte, Amgen, Novartis, AstraZeneca/MedImmune (Inst), Mirati Therapeutics, Gritstone Bio, Jazz Pharmaceuticals, Merck (Inst), Bristol Myers Squibb (Inst), Takeda, Janssen Research &amp; Development, Mersana, Blueprint Medicines (Inst), Daiichi Sankyo/Astra Zeneca, Regeneron</p>
                    <p><bold>Research Funding:</bold> Roche (Inst), AstraZeneca (Inst), Boehringer Ingelheim (Inst), Astellas Pharma (Inst), MedImmune (Inst), Novartis (Inst), Newlink Genetics (Inst), Incyte (Inst), AbbVie (Inst), Ignyta (Inst), LAM Therapeutics (Inst), Trovagene (Inst), Takeda (Inst), Macrogenics (Inst), CytomX Therapeutics (Inst), Astex Pharmaceuticals (Inst), Bristol Myers Squibb (Inst), Loxo (Inst), Arch Therapeutics (Inst), Gritstone Bio (Inst), Plexxikon (Inst), Amgen (Inst), Loxo (Inst), Daiichi Sankyo (Inst), ADC Therapeutics (Inst), Janssen Oncology (Inst), Mirati Therapeutics (Inst), Rubius Therapeutics (Inst), Synthekine (Inst), Mersana (Inst), Blueprint Medicines (Inst), Regeneron, Alkermes (Inst), Revolution Medicines (Inst)</p>
                  </fn>
                  <fn id="con11" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Elysa Noon</bold>
                    </p>
                    <p><bold>Employment:</bold> AbbVie</p>
                    <p><bold>Stock and Other Ownership Interests:</bold> AbbVie</p>
                  </fn>
                  <fn id="con12" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Fabrice Barlesi</bold>
                    </p>
                    <p><bold>Honoraria:</bold> Genentech/Roche, Pfizer, Pierre Fabre, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Lilly, Novartis, Merck Serono, MSD Oncology, Takeda, Bayer, Seattle Genetics, Mirati Therapeutics</p>
                    <p><bold>Consulting or Advisory Role:</bold> Roche/Genentech, Pfizer, Novartis, Pierre Fabre, Bristol Myers Squibb, AstraZeneca/MedImmune, Boehringer Ingelheim, Lilly, Merck Serono, MSD Oncology, Takeda, Bayer, Mirati Therapeutics</p>
                    <p><bold>Research Funding:</bold> Roche/Genentech (Inst), AstraZeneca/MedImmune (Inst), Bristol Myers Squibb (Inst), Pierre Fabre (Inst), AbbVie (Inst), Amgen (Inst), Bayer (Inst), Boehringer Ingelheim (Inst), Eisai (Inst), Lilly (Inst), Ipsen (Inst), Innate Pharma (Inst), Novartis (Inst), Merck Serono (Inst), MSD Oncology (Inst), Pfizer (Inst), Sanofi/Aventis (Inst), Takeda (Inst)</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Roche/Genentech, Bristol Myers Squibb, AstraZeneca/MedImmune, MSD Oncology</p>
                  </fn>
                  <fn id="con13" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Karen Kelly</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> AstraZeneca, Regeneron, Novartis, Takeda, Lilly, Amgen, EMD Serono, Genmab, Targeted Oncology, Genentech, Debiopharm Group, AbbVie, Daiichi Sanko, Janssen, Eisai, Sanofi</p>
                    <p><bold>Research Funding:</bold> EMD Serono (Inst), Genentech (Inst), AbbVie (Inst), Regeneron (Inst), Astellas Pharma (Inst), Tizona Therapeutics, Inc (Inst), Lilly (Inst), Novartis (Inst), Amgen (Inst), Bristol Myers Squibb (Inst), Five Prime Therapeutics (Inst), Jounce Therapeutics (Inst)</p>
                    <p><bold>Patents, Royalties, Other Intellectual Property:</bold> Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA</p>
                  </fn>
                  <fn id="con14" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Daniel Morgensztern</bold>
                    </p>
                    <p><bold>Stock and Other Ownership Interests:</bold> Bristol Myers Squibb/Medarex, Abbott Laboratories</p>
                    <p><bold>Consulting or Advisory Role:</bold> Bristol Myers Squibb, AbbVie, G1 Therapeutics, Lilly Medical, Mirati Therapeutics, Arcus Biosciences</p>
                    <p><bold>Research Funding:</bold> Heat Biologics (Inst), Merck (Inst), Celgene (Inst), AstraZeneca (Inst), Baxter (Inst), Incyte (Inst), AbbVie (Inst), Bristol Myers Squibb (Inst), EpicentRx (Inst), Pfizer (Inst), Roche (Inst), Lilly (Inst), Altum Pharmaceuticals (Inst), Array BioPharma (Inst), Surface Oncology (Inst), Arcus Biosciences (Inst), Boehringer Ingelheim (Inst), Y-mAbs Therapeutics (Inst)</p>
                  </fn>
                  <fn id="con15" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Monica Motwani</bold>
                    </p>
                    <p><bold>Employment:</bold> AbbVie, Gilead Sciences, GlaxoSmithKline</p>
                    <p><bold>Stock and Other Ownership Interests:</bold> Gilead Sciences, AbbVie</p>
                    <p><bold>Patents, Royalties, Other Intellectual Property:</bold> A patent on the DR4/5 and KRAS relationship. Patent filed by AbbVie and I am listed as a coinventor. No royalties are received</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Gilead Sciences, AbbVie</p>
                  </fn>
                  <fn id="con16" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Everett Vokes</bold>
                    </p>
                    <p><bold>Stock and Other Ownership Interests:</bold> Coordination Pharmaceuticals, McKesson</p>
                    <p><bold>Honoraria:</bold> Takeda, Ascendis Pharma</p>
                    <p><bold>Consulting or Advisory Role:</bold> Takeda, Ascendis Pharma, Bristol Myers Squibb/Sanofi, EMD Serono</p>
                    <p><bold>Research Funding:</bold> AbbVie, Bristol Myers Squibb, Celgene, Novartis, Lilly (Inst)</p>
                    <p>
                      <bold>Open Payments Link:</bold>
                      <ext-link xlink:href="https://openpaymentsdata.cms.gov/physician/930740" ext-link-type="uri">https://openpaymentsdata.cms.gov/physician/930740</ext-link>
                    </p>
                  </fn>
                  <fn id="con17" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Apurvasena Parikh</bold>
                    </p>
                    <p><bold>Employment:</bold> AbbVie</p>
                    <p><bold>Stock and Other Ownership Interests:</bold> AbbVie</p>
                    <p>No other potential conflicts of interest were reported.</p>
                  </fn>
                </fn-group>
              </sec>
            </sec>
            <notes>
              <fn-group content-type="COI-statement">
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>D. Ross Camidge</bold>
                  </p>
                  <p><bold>Honoraria:</bold> Roche, Takeda, AstraZeneca, Daiichi Sankyo, Bio-Thera, Ribon Therapeutics, AbbVie, Apollomics, Elevation Oncology, EMD Serono, Helsinn Therapeutics, Lilly, Nuvalent, Inc, Seattle Genetics, Kestrel Labs, Amgen Astellas BioPharma, Janssen, OnKure, Mersana, Sanofi, Anheart Therapeutics, BeiGene, Hengrui Pharmaceutical, Puma Biotechnology, Turning Point Therapeutics, BeiGene, Dizal Pharma, Hummingbird, Mirati Therapeutics, Nalo</p>
                  <p><bold>Research Funding:</bold> Inivata (Inst)</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Wu-Chou Su</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Bayer Schering Pharma, MSD Oncology, Lilly, Merck</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Jun Wu</bold>
                  </p>
                  <p><bold>Employment:</bold> AbbVie</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> AbbVie</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Jonathan W. Goldman</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> AstraZeneca, Bristol Myers Squibb, Lilly, Amgen, Pfizer</p>
                  <p><bold>Research Funding:</bold> Lilly (Inst), Genentech/Roche (Inst), Bristol Myers Squibb (Inst), AstraZeneca/MedImmune (Inst), Array BioPharma (Inst), AbbVie (Inst), Corvus Pharmaceuticals (Inst), Spectrum Pharmaceuticals (Inst), Advaxis (Inst), Pfizer (Inst)</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> AstraZeneca</p>
                  <p>
                    <bold>Open Payments Link:</bold>
                    <ext-link xlink:href="https://openpaymentsdata.cms.gov/physician/124819" ext-link-type="uri">https://openpaymentsdata.cms.gov/physician/124819</ext-link>
                  </p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>John H. Strickler</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Bayer, Natera (Inst), Pfizer, Mereo Biopharma, AstraZeneca, Viatris, Seattle Genetics, Roche/Genentech (Inst), Inivata, Silverback Therapeutics, GlaxoSmithKline, Pionyr, AbbVie, Takeda, Zentalis</p>
                  <p><bold>Research Funding:</bold> AbbVie (Inst), Roche/Genentech (Inst), Leap Therapeutics (Inst), Nektar (Inst), Amgen (Inst), Curegenix (Inst), A*STAR (Inst), Bayer (Inst), AstraZeneca/MedImmune (Inst), Sanofi (Inst), Daiichi Sankyo/Lilly, Silverback Therapeutics (Inst), Erasca, Inc (Inst), Seattle Genetics (Inst)</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Guardant Health, Seattle Genetics</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Eric Angevin</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> MedImmune, Celgene, GlaxoSmithKline, Merck Sharp &amp; Dohme, Roche</p>
                  <p><bold>Research Funding:</bold> AbbVie, Pfizer, GlaxoSmithKline, Sanofi, MedImmune, Octimet</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Innate Pharma, Celgene, GlaxoSmithKline, AbbVie, Bristol Myers Squibb, AstraZeneca</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Vincent Blot</bold>
                  </p>
                  <p><bold>Employment:</bold> AbbVie</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> AbbVie</p>
                  <p><bold>Research Funding:</bold> AbbVie</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> AbbVie</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Rebecca Heist</bold>
                  </p>
                  <p><bold>Honoraria:</bold> Chugai/Roche</p>
                  <p><bold>Consulting or Advisory Role:</bold> Novartis, Daichii Sankyo, EMD Serono/Merck, AbbVie</p>
                  <p><bold>Research Funding:</bold> AbbVie (Inst), Novartis (Inst), Roche (Inst), Incyte (Inst), Celgene (Inst), Mirati Therapeutics (Inst), Peregrine Pharmaceuticals (Inst), Exelixis (Inst), Millennium (Inst), Debiopharm Group (Inst), Corvus Pharmaceuticals (Inst), Daiichi Sankyo (Inst), Agios (Inst), Exelixis (Inst), Pfizer (Inst), Lilly (Inst), Turning Point Therapeutics (Inst)</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Martin Dunbar</bold>
                  </p>
                  <p><bold>Employment:</bold> AbbVie</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> AbbVie</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Alex Spira</bold>
                  </p>
                  <p><bold>Leadership:</bold> Next Oncology (Inst)</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Lilly</p>
                  <p><bold>Honoraria:</bold> CytomX Therapeutics, AstraZeneca/MedImmune, Merck, Takeda, Amgen, Janssen Oncology, Novartis, Bristol Myers Squibb, Bayer</p>
                  <p><bold>Consulting or Advisory Role:</bold> Array BioPharma (Inst), Incyte, Amgen, Novartis, AstraZeneca/MedImmune (Inst), Mirati Therapeutics, Gritstone Bio, Jazz Pharmaceuticals, Merck (Inst), Bristol Myers Squibb (Inst), Takeda, Janssen Research &amp; Development, Mersana, Blueprint Medicines (Inst), Daiichi Sankyo/Astra Zeneca, Regeneron</p>
                  <p><bold>Research Funding:</bold> Roche (Inst), AstraZeneca (Inst), Boehringer Ingelheim (Inst), Astellas Pharma (Inst), MedImmune (Inst), Novartis (Inst), Newlink Genetics (Inst), Incyte (Inst), AbbVie (Inst), Ignyta (Inst), LAM Therapeutics (Inst), Trovagene (Inst), Takeda (Inst), Macrogenics (Inst), CytomX Therapeutics (Inst), Astex Pharmaceuticals (Inst), Bristol Myers Squibb (Inst), Loxo (Inst), Arch Therapeutics (Inst), Gritstone Bio (Inst), Plexxikon (Inst), Amgen (Inst), Loxo (Inst), Daiichi Sankyo (Inst), ADC Therapeutics (Inst), Janssen Oncology (Inst), Mirati Therapeutics (Inst), Rubius Therapeutics (Inst), Synthekine (Inst), Mersana (Inst), Blueprint Medicines (Inst), Regeneron, Alkermes (Inst), Revolution Medicines (Inst)</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Elysa Noon</bold>
                  </p>
                  <p><bold>Employment:</bold> AbbVie</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> AbbVie</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Fabrice Barlesi</bold>
                  </p>
                  <p><bold>Honoraria:</bold> Genentech/Roche, Pfizer, Pierre Fabre, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Lilly, Novartis, Merck Serono, MSD Oncology, Takeda, Bayer, Seattle Genetics, Mirati Therapeutics</p>
                  <p><bold>Consulting or Advisory Role:</bold> Roche/Genentech, Pfizer, Novartis, Pierre Fabre, Bristol Myers Squibb, AstraZeneca/MedImmune, Boehringer Ingelheim, Lilly, Merck Serono, MSD Oncology, Takeda, Bayer, Mirati Therapeutics</p>
                  <p><bold>Research Funding:</bold> Roche/Genentech (Inst), AstraZeneca/MedImmune (Inst), Bristol Myers Squibb (Inst), Pierre Fabre (Inst), AbbVie (Inst), Amgen (Inst), Bayer (Inst), Boehringer Ingelheim (Inst), Eisai (Inst), Lilly (Inst), Ipsen (Inst), Innate Pharma (Inst), Novartis (Inst), Merck Serono (Inst), MSD Oncology (Inst), Pfizer (Inst), Sanofi/Aventis (Inst), Takeda (Inst)</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Roche/Genentech, Bristol Myers Squibb, AstraZeneca/MedImmune, MSD Oncology</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Karen Kelly</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> AstraZeneca, Regeneron, Novartis, Takeda, Lilly, Amgen, EMD Serono, Genmab, Targeted Oncology, Genentech, Debiopharm Group, AbbVie, Daiichi Sanko, Janssen, Eisai, Sanofi</p>
                  <p><bold>Research Funding:</bold> EMD Serono (Inst), Genentech (Inst), AbbVie (Inst), Regeneron (Inst), Astellas Pharma (Inst), Tizona Therapeutics, Inc (Inst), Lilly (Inst), Novartis (Inst), Amgen (Inst), Bristol Myers Squibb (Inst), Five Prime Therapeutics (Inst), Jounce Therapeutics (Inst)</p>
                  <p><bold>Patents, Royalties, Other Intellectual Property:</bold> Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Daniel Morgensztern</bold>
                  </p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Bristol Myers Squibb/Medarex, Abbott Laboratories</p>
                  <p><bold>Consulting or Advisory Role:</bold> Bristol Myers Squibb, AbbVie, G1 Therapeutics, Lilly Medical, Mirati Therapeutics, Arcus Biosciences</p>
                  <p><bold>Research Funding:</bold> Heat Biologics (Inst), Merck (Inst), Celgene (Inst), AstraZeneca (Inst), Baxter (Inst), Incyte (Inst), AbbVie (Inst), Bristol Myers Squibb (Inst), EpicentRx (Inst), Pfizer (Inst), Roche (Inst), Lilly (Inst), Altum Pharmaceuticals (Inst), Array BioPharma (Inst), Surface Oncology (Inst), Arcus Biosciences (Inst), Boehringer Ingelheim (Inst), Y-mAbs Therapeutics (Inst)</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Monica Motwani</bold>
                  </p>
                  <p><bold>Employment:</bold> AbbVie, Gilead Sciences, GlaxoSmithKline</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Gilead Sciences, AbbVie</p>
                  <p><bold>Patents, Royalties, Other Intellectual Property:</bold> A patent on the DR4/5 and KRAS relationship. Patent filed by AbbVie and I am listed as a coinventor. No royalties are received</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Gilead Sciences, AbbVie</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Everett Vokes</bold>
                  </p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Coordination Pharmaceuticals, McKesson</p>
                  <p><bold>Honoraria:</bold> Takeda, Ascendis Pharma</p>
                  <p><bold>Consulting or Advisory Role:</bold> Takeda, Ascendis Pharma, Bristol Myers Squibb/Sanofi, EMD Serono</p>
                  <p><bold>Research Funding:</bold> AbbVie, Bristol Myers Squibb, Celgene, Novartis, Lilly (Inst)</p>
                  <p>
                    <bold>Open Payments Link:</bold>
                    <ext-link xlink:href="https://openpaymentsdata.cms.gov/physician/930740" ext-link-type="uri">https://openpaymentsdata.cms.gov/physician/930740</ext-link>
                  </p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Apurvasena Parikh</bold>
                  </p>
                  <p><bold>Employment:</bold> AbbVie</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> AbbVie</p>
                  <p>No other potential conflicts of interest were reported.</p>
                </fn>
              </fn-group>
            </notes>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="b1">
                <label>1.</label>
                <mixed-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Ervik</surname><given-names>M</given-names></name><name><surname>Lam</surname><given-names>F</given-names></name><etal/></person-group> (eds): <source>Cancer Today (Powered by GLOBOCAN 2020)</source>. <publisher-loc>Lyon</publisher-loc>, <publisher-name>International Agency for Research on Cancer</publisher-name>, <year>2020</year>. <comment><ext-link xlink:href="https://gco.iarc.fr/today" ext-link-type="uri">https://gco.iarc.fr/today</ext-link></comment></mixed-citation>
              </ref>
              <ref id="b2">
                <label>2.</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Howlander</surname><given-names>N</given-names></name><name><surname>Noone</surname><given-names>AM</given-names></name><name><surname>Krapcho</surname><given-names>M</given-names></name><etal/></person-group>: <source>SEER Cancer Statistics Review</source>. <publisher-loc>Bethesda, MD</publisher-loc>, <publisher-name>National Cancer Institute</publisher-name>, <year>2020</year>, pp <fpage>1975</fpage>-<lpage>2017</lpage>. <comment><ext-link xlink:href="https://seer.cancer.gov/csr/1975_2017" ext-link-type="uri">https://seer.cancer.gov/csr/1975_2017</ext-link></comment></mixed-citation>
              </ref>
              <ref id="b3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>CS</given-names></name><name><surname>Park</surname><given-names>M</given-names></name><name><surname>Blair</surname><given-names>DG</given-names></name><etal/></person-group>: <article-title>Molecular cloning of a new transforming gene from a chemically transformed human cell line</article-title>. <source>Nature</source><volume>311</volume>:<fpage>29</fpage>-<lpage>33</lpage>, <year>1984</year><pub-id pub-id-type="pmid">6590967</pub-id></mixed-citation>
              </ref>
              <ref id="b4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bottaro</surname><given-names>DP</given-names></name><name><surname>Rubin</surname><given-names>JS</given-names></name><name><surname>Faletto</surname><given-names>DL</given-names></name><etal/></person-group>: <article-title>Identification of the hepatocyte growth factor receptor as the c-Met proto-oncogene product</article-title>. <source>Science</source><volume>251</volume>:<fpage>802</fpage>-<lpage>804</lpage>, <year>1991</year><pub-id pub-id-type="pmid">1846706</pub-id></mixed-citation>
              </ref>
              <ref id="b5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olivero</surname><given-names>M</given-names></name><name><surname>Rizzo</surname><given-names>M</given-names></name><name><surname>Madeddu</surname><given-names>R</given-names></name><etal/></person-group>: <article-title>Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas</article-title>. <source>Br J Cancer</source><volume>74</volume>:<fpage>1862</fpage>-<lpage>1868</lpage>, <year>1996</year><pub-id pub-id-type="pmid">8980383</pub-id></mixed-citation>
              </ref>
              <ref id="b6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>PC</given-names></name><name><surname>Tretiakova</surname><given-names>MS</given-names></name><name><surname>MacKinnon</surname><given-names>AC</given-names></name><etal/></person-group>: <article-title>Expression and mutational analysis of MET in human solid cancers</article-title>. <source>Genes Chromosomes Cancer</source><volume>47</volume>:<fpage>1025</fpage>-<lpage>1037</lpage>, <year>2008</year><pub-id pub-id-type="pmid">18709663</pub-id></mixed-citation>
              </ref>
              <ref id="b7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spigel</surname><given-names>DR</given-names></name><name><surname>Ervin</surname><given-names>TJ</given-names></name><name><surname>Ramlau</surname><given-names>RA</given-names></name><etal/></person-group>: <article-title>Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer</article-title>. <source>J Clin Oncol</source><volume>31</volume>:<fpage>4105</fpage>-<lpage>4114</lpage>, <year>2013</year><pub-id pub-id-type="pmid">24101053</pub-id></mixed-citation>
              </ref>
              <ref id="b8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heist</surname><given-names>RS</given-names></name><name><surname>Motwani</surname><given-names>M</given-names></name><name><surname>Barlesi</surname><given-names>F</given-names></name><etal/></person-group>: <article-title>c-Met expression and response to telisotuzumab vedotin (Teliso-v) in patients with non-small cell lung cancer</article-title>. <source>J Clin Oncol</source><volume>37</volume>:<fpage>9023</fpage>-<lpage>90123</lpage>, <year>2019</year><comment>(suppl 15)</comment></mixed-citation>
              </ref>
              <ref id="b9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camidge</surname><given-names>DR</given-names></name><name><surname>Goldman</surname><given-names>JW</given-names></name><name><surname>Cole</surname><given-names>GW</given-names></name><etal/></person-group>: <article-title>Evaluating telisotuzumab vedotin in combination with osimertinib in patients with advanced non-small cell lung cancer: A phase I/Ib study cohort</article-title>. <source>Ann Oncol</source><volume>31</volume>:<fpage>S894</fpage>, <year>2020</year> (<comment>suppl; abstr 1414TiP</comment>)</mixed-citation>
              </ref>
              <ref id="b10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onozato</surname><given-names>R</given-names></name><name><surname>Kosaka</surname><given-names>T</given-names></name><name><surname>Kuwano</surname><given-names>H</given-names></name><etal/></person-group>: <article-title>Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers</article-title>. <source>J Thorac Oncol</source><volume>4</volume>:<fpage>5</fpage>-<lpage>11</lpage>, <year>2009</year><pub-id pub-id-type="pmid">19096300</pub-id></mixed-citation>
              </ref>
              <ref id="b11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research Network</collab></person-group>: <article-title>Comprehensive molecular profiling of lung adenocarcinoma</article-title>. <source>Nature</source><volume>511</volume>:<fpage>543</fpage>-<lpage>550</lpage>, <year>2014</year><pub-id pub-id-type="pmid">25079552</pub-id></mixed-citation>
              </ref>
              <ref id="b12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>KD</given-names></name><name><surname>Ng</surname><given-names>TL</given-names></name><name><surname>Estrada-Bernal</surname><given-names>A</given-names></name><etal/></person-group>: <article-title>Dramatic response to crizotinib in a patient with lung cancer positive for an <italic toggle="yes">HLA-DRB1-MET</italic> gene fusion</article-title>. <source>JCO Precis Oncol</source><ext-link xlink:href="http://10.1200/PO.17.00117" ext-link-type="uri">10.1200/PO.17.00117</ext-link></mixed-citation>
              </ref>
              <ref id="b13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bean</surname><given-names>J</given-names></name><name><surname>Brennan</surname><given-names>C</given-names></name><name><surname>Shih</surname><given-names>JY</given-names></name><etal/></person-group>: <article-title>MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib</article-title>. <source>Proc Natl Acad Sci U S A</source><volume>104</volume>:<fpage>20932</fpage>-<lpage>20937</lpage>, <year>2007</year><pub-id pub-id-type="pmid">18093943</pub-id></mixed-citation>
              </ref>
              <ref id="b14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engelman</surname><given-names>JA</given-names></name><name><surname>Zejnullahu</surname><given-names>K</given-names></name><name><surname>Mitsudomi</surname><given-names>T</given-names></name><etal/></person-group>: <article-title>MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling</article-title>. <source>Science</source><volume>316</volume>:<fpage>1039</fpage>-<lpage>1043</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17463250</pub-id></mixed-citation>
              </ref>
              <ref id="b15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>MG</given-names></name><name><surname>Oleksijew</surname><given-names>A</given-names></name><etal/></person-group>: <article-title>ABBV-399, a c-Met antibody-drug conjugate that targets both <italic toggle="yes">MET</italic>-amplified and c-Met-overexpressing tumors, irrespective of <italic toggle="yes">MET</italic> pathway dependence</article-title>. <source>Clin Cancer Res</source><volume>23</volume>:<fpage>992</fpage>-<lpage>1000</lpage>, <year>2017</year><pub-id pub-id-type="pmid">27573171</pub-id></mixed-citation>
              </ref>
              <ref id="b16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strickler</surname><given-names>JH</given-names></name><name><surname>Weekes</surname><given-names>CD</given-names></name><name><surname>Nemunaitis</surname><given-names>J</given-names></name><etal/></person-group>: <article-title>First-in-human phase I, dose-escalation and expansion study of telisotuzumab vedotin, an antibody-drug conjugate targeting c-Met, in patients with advanced solid tumors</article-title>. <source>J Clin Oncol</source><volume>36</volume>:<fpage>3298</fpage>-<lpage>3306</lpage>, <year>2018</year><pub-id pub-id-type="pmid">30285518</pub-id></mixed-citation>
              </ref>
              <ref id="b17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shepherd</surname><given-names>FA</given-names></name><name><surname>Rodrigues Pereira</surname><given-names>J</given-names></name><name><surname>Ciuleanu</surname><given-names>T</given-names></name><etal/></person-group>: <article-title>Erlotinib in previously treated non-small-cell lung cancer</article-title>. <source>N Engl J Med</source><volume>353</volume>:<fpage>123</fpage>-<lpage>132</lpage>, <year>2005</year><pub-id pub-id-type="pmid">16014882</pub-id></mixed-citation>
              </ref>
              <ref id="b18">
                <label>18.</label>
                <mixed-citation publication-type="webpage"><comment>OSI Pharmaceuticals: TARCEVA (Erlotinib) [prescribing information]</comment>. <comment><ext-link xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf</ext-link></comment></mixed-citation>
              </ref>
              <ref id="b19">
                <label>19.</label>
                <mixed-citation publication-type="webpage"><comment>AstraZeneca Pharmaceuticals LP: IRESSA (Gefitinib Tablets) [prescribing information]</comment>. <comment><ext-link xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021399lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021399lbl.pdf</ext-link></comment></mixed-citation>
              </ref>
              <ref id="b20">
                <label>20.</label>
                <mixed-citation publication-type="webpage"><comment>Boehringer Ingelheim Pharmaceuticals: GILOTRIF (Afatinib) [prescribing information]</comment>. <comment><ext-link xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/201292s014lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/201292s014lbl.pdf</ext-link></comment></mixed-citation>
              </ref>
              <ref id="b21">
                <label>21.</label>
                <mixed-citation publication-type="webpage"><comment>AstraZeneca Pharmaceuticals LP: TAGRISSO (Osimertinib) [prescribing information]</comment>. <comment><ext-link xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208065s000lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208065s000lbl.pdf</ext-link></comment></mixed-citation>
              </ref>
              <ref id="b22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Planchard</surname><given-names>D</given-names></name><name><surname>Popat</surname><given-names>S</given-names></name><name><surname>Kerr</surname><given-names>K</given-names></name><etal/></person-group>: <article-title>Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</article-title>. <source>Ann Oncol</source><volume>29</volume>:<fpage>iv192</fpage>-<lpage>iv237</lpage>, <year>2018</year><pub-id pub-id-type="pmid">30285222</pub-id></mixed-citation>
              </ref>
              <ref id="b23">
                <label>23.</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><collab>National Comprehensive Cancer Network</collab></person-group>: <source>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>). Non-Small Cell Lung Cancer. Version 7</source>. <year>2021</year>. <comment><ext-link xlink:href="http://www.nccn.org/professionals/physician_gls/default.aspx" ext-link-type="uri">http://www.nccn.org/professionals/physician_gls/default.aspx</ext-link></comment></mixed-citation>
              </ref>
              <ref id="b24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>A</given-names></name><name><surname>Villén</surname><given-names>J</given-names></name><name><surname>Kornhauser</surname><given-names>J</given-names></name><etal/></person-group>: <article-title>Signaling networks assembled by oncogenic EGFR and c-Met</article-title>. <source>Proc Natl Acad Sci U S A</source><volume>105</volume>:<fpage>692</fpage>-<lpage>697</lpage>, <year>2008</year><pub-id pub-id-type="pmid">18180459</pub-id></mixed-citation>
              </ref>
              <ref id="b25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turke</surname><given-names>AB</given-names></name><name><surname>Zejnullahu</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>YL</given-names></name><etal/></person-group>: <article-title>Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC</article-title>. <source>Cancer Cell</source><volume>17</volume>:<fpage>77</fpage>-<lpage>88</lpage>, <year>2010</year><pub-id pub-id-type="pmid">20129249</pub-id></mixed-citation>
              </ref>
              <ref id="b26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsubara</surname><given-names>D</given-names></name><name><surname>Ishikawa</surname><given-names>S</given-names></name><name><surname>Sachiko</surname><given-names>O</given-names></name><etal/></person-group>: <article-title>Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas</article-title>. <source>Am J Pathol</source><volume>177</volume>:<fpage>2191</fpage>-<lpage>2204</lpage>, <year>2010</year><pub-id pub-id-type="pmid">20934974</pub-id></mixed-citation>
              </ref>
              <ref id="b27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soria</surname><given-names>JC</given-names></name><name><surname>Ohe</surname><given-names>Y</given-names></name><name><surname>Vansteenkiste</surname><given-names>J</given-names></name><etal/></person-group>: <article-title>Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer</article-title>. <source>N Engl J Med</source><volume>378</volume>:<fpage>113</fpage>-<lpage>125</lpage>, <year>2018</year><pub-id pub-id-type="pmid">29151359</pub-id></mixed-citation>
              </ref>
              <ref id="b28">
                <label>28.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramalingam</surname><given-names>SS</given-names></name><name><surname>Vansteenkiste</surname><given-names>J</given-names></name><name><surname>Planchard</surname><given-names>D</given-names></name><etal/></person-group>: <article-title>Overall survival with osimertinib in untreated, <italic toggle="yes">EGFR</italic>-mutated advanced NSCLC</article-title>. <source>N Engl J Med</source><volume>382</volume>:<fpage>41</fpage>-<lpage>50</lpage>, <year>2020</year><pub-id pub-id-type="pmid">31751012</pub-id></mixed-citation>
              </ref>
              <ref id="b29">
                <label>29.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camidge</surname><given-names>DR</given-names></name><name><surname>Morgensztern</surname><given-names>D</given-names></name><name><surname>Heist</surname><given-names>RS</given-names></name><etal/></person-group>: <article-title>Phase I study of 2- or 3-week dosing of telisotuzumab vedotin, and antibody-drug conjugate targeting c-Met, monotherapy in patients with advanced non-small cell lung carcinoma</article-title>. <source>Clin Cancer Res</source><volume>27</volume>:<fpage>5781</fpage>-<lpage>5792</lpage>, <year>2021</year><pub-id pub-id-type="pmid">34426443</pub-id></mixed-citation>
              </ref>
              <ref id="b30">
                <label>30.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masters</surname><given-names>JC</given-names></name><name><surname>Nickens</surname><given-names>DJ</given-names></name><name><surname>Xuan</surname><given-names>D</given-names></name><etal/></person-group>: <article-title>Clinical toxicity of antibody drug conjugates: A meta-analysis of payloads</article-title>. <source>Invest New Drugs</source><volume>36</volume>:<fpage>121</fpage>-<lpage>135</lpage>, <year>2018</year><pub-id pub-id-type="pmid">29027591</pub-id></mixed-citation>
              </ref>
              <ref id="b31">
                <label>31.</label>
                <mixed-citation publication-type="webpage"><comment>Seattle Genetics: ADCETRIS (Brentuximab Vedotin) [prescribing information]</comment>. <comment><ext-link xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_s056s078lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_s056s078lbl.pdf</ext-link></comment></mixed-citation>
              </ref>
              <ref id="b32">
                <label>32.</label>
                <mixed-citation publication-type="webpage"><comment>Astellas Pharma US: PADCEV (Enfortumab Vedotin-Ejfv) [prescribing information]</comment>. <comment><ext-link xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf</ext-link></comment></mixed-citation>
              </ref>
              <ref id="b33">
                <label>33.</label>
                <mixed-citation publication-type="webpage"><comment>Genentech: POLIVY (Polatuzumab Vedotin-Piiq) [prescribing information]</comment>. <comment><ext-link xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf</ext-link></comment></mixed-citation>
              </ref>
              <ref id="b34">
                <label>34.</label>
                <mixed-citation publication-type="webpage"><comment>Seagen: TIVDAK (Tisotumab Vedotin-Tftv) [prescribing information]</comment>. <comment><ext-link xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761208Orig1s000lbledt.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761208Orig1s000lbledt.pdf</ext-link></comment></mixed-citation>
              </ref>
              <ref id="b35">
                <label>35.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kågedal</surname><given-names>M</given-names></name><name><surname>Samineni</surname><given-names>D</given-names></name><name><surname>Gillespie</surname><given-names>WR</given-names></name><etal/></person-group>: <article-title>Time-to-event modeling of peripheral neuropathy: Platform analysis of eight valine-citrulline-monomethylauristatin E antibody-drug conjugates</article-title>. <source>CPT Pharmacometrics Syst Pharmacol</source><volume>8</volume>:<fpage>606</fpage>-<lpage>615</lpage>, <year>2019</year><pub-id pub-id-type="pmid">31207190</pub-id></mixed-citation>
              </ref>
              <ref id="b36">
                <label>36.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Methvin</surname><given-names>AB</given-names></name><name><surname>Gausas</surname><given-names>RE</given-names></name></person-group>: <article-title>Newly recognized ocular side effects of erlotinib</article-title>. <source>Ophthalmic Plast Reconstr Surg</source><volume>23</volume>:<fpage>63</fpage>-<lpage>65</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17237697</pub-id></mixed-citation>
              </ref>
              <ref id="b37">
                <label>37.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>HD</given-names></name><name><surname>Chang</surname><given-names>MJ</given-names></name></person-group>: <article-title>Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis</article-title>. <source>PLoS One</source><volume>15</volume>:<fpage>e0234818</fpage>, <year>2020</year><pub-id pub-id-type="pmid">32663210</pub-id></mixed-citation>
              </ref>
              <ref id="b38">
                <label>38.</label>
                <mixed-citation publication-type="webpage"><comment>GlaxoSmithKline: BLENREP (Belantamab Mafodotin-Blmf) [prescribing information]</comment>. <comment><ext-link xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf</ext-link></comment></mixed-citation>
              </ref>
              <ref id="b39">
                <label>39.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paik</surname><given-names>PK</given-names></name><name><surname>Felip</surname><given-names>E</given-names></name><name><surname>Veillon</surname><given-names>R</given-names></name><etal/></person-group>: <article-title>Tepotinib in non-small-cell lung cancer with <italic toggle="yes">MET</italic> exon 14 skipping mutations</article-title>. <source>N Engl J Med</source><volume>383</volume>:<fpage>931</fpage>-<lpage>943</lpage>, <year>2020</year><pub-id pub-id-type="pmid">32469185</pub-id></mixed-citation>
              </ref>
              <ref id="b40">
                <label>40.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>J</given-names></name><name><surname>Seto</surname><given-names>T</given-names></name><name><surname>Han</surname><given-names>JY</given-names></name><etal/></person-group>: <article-title>Capmatinib in <italic toggle="yes">MET</italic> exon 14-mutated or <italic toggle="yes">MET</italic>-amplified non-small-cell lung cancer</article-title>. <source>N Engl J Med</source><volume>383</volume>:<fpage>944</fpage>-<lpage>957</lpage>, <year>2020</year><pub-id pub-id-type="pmid">32877583</pub-id></mixed-citation>
              </ref>
              <ref id="b41">
                <label>41.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markóczy</surname><given-names>Z</given-names></name><name><surname>Sárosi</surname><given-names>V</given-names></name><name><surname>Kudaba</surname><given-names>I</given-names></name><etal/></person-group>: <article-title>Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): An open-label, non-randomized, multicenter, phase IV clinical trial</article-title>. <source>BMC Cancer</source><volume>18</volume>:<fpage>598</fpage>, <year>2018</year><pub-id pub-id-type="pmid">29801465</pub-id></mixed-citation>
              </ref>
              <ref id="b42">
                <label>42.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>H</given-names></name><name><surname>Fukuhara</surname><given-names>T</given-names></name><name><surname>Furuya</surname><given-names>N</given-names></name><etal/></person-group>: <article-title>Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): Interim analysis of an open-label, randomised, multicentre, phase 3 trial</article-title>. <source>Lancet Oncol</source><volume>20</volume>:<fpage>625</fpage>-<lpage>635</lpage>, <year>2019</year><pub-id pub-id-type="pmid">30975627</pub-id></mixed-citation>
              </ref>
              <ref id="b43">
                <label>43.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>YL</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Kim</surname><given-names>DW</given-names></name><etal/></person-group>: <article-title>Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer</article-title>. <source>J Clin Oncol</source><volume>36</volume>:<fpage>3101</fpage>-<lpage>3109</lpage>, <year>2018</year>. <comment>Erratum in J Clin Oncol 37:261, 2019</comment><pub-id pub-id-type="pmid">30156984</pub-id></mixed-citation>
              </ref>
              <ref id="b44">
                <label>44.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>DS</given-names></name><name><surname>LoRusso</surname><given-names>P</given-names></name><name><surname>Hamid</surname><given-names>O</given-names></name><etal/></person-group>: <article-title>Phase I study of AMG 337, a highly selective small-molecule MET inhibitor, in patients with advanced solid tumors</article-title>. <source>Clin Cancer Res</source><volume>25</volume>:<fpage>2403</fpage>-<lpage>2413</lpage>, <year>2019</year><pub-id pub-id-type="pmid">30425090</pub-id></mixed-citation>
              </ref>
              <ref id="b45">
                <label>45.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Le</surname><given-names>X</given-names></name><name><surname>Costa</surname><given-names>DB</given-names></name></person-group>: <article-title>The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer</article-title>. <source>Expert Rev Anticancer Ther</source><volume>16</volume>:<fpage>383</fpage>-<lpage>390</lpage>, <year>2016</year><pub-id pub-id-type="pmid">26943236</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
